Hepatitis B - Pipeline Assessment and Market Forecasts to 2017

Date: September 1, 2010
Pages: 41
Price:
US$ 2,000.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: HD7F8C7C3D9EN
Leaflet:

Download PDF Leaflet

Hepatitis B - Pipeline Assessment and Market Forecasts to 2017
Hepatitis B
- Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, “Hepatitis B - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Hepatitis B therapeutics market. The report identifies the key trends shaping and driving the global Hepatitis B therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global Hepatitis B sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData estimates the global Hepatitis B (Hepatitis B) therapeutics market to be valued at $1.3bn in 2009. The market is estimated to grow up to $1.5bn in 2017, with a compound annual growth rate (CAGR) of 1.3%. This slow growth is attributed to the patent expiry of Baraclude in 2015. Growth in the Hepatitis B market will be driven by the increase in the number of patients. The US is the largest market for Hepatitis B and it contributes to approximately 50% of the global market

Scope

The scope of the report includes:

- Annualized global Hepatitis B therapeutics market revenue data from 2001 to 2009, forecast for eight years to 2017.

- Geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France and Japan.

- Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include nucleoside analogs, nucleotide analogs, interferons and glucocorticoids.

- Analysis of the current and future market competition in the global Hepatitis B therapeutics market. The key future market players covered are Novartis, Gilead Sciences, Bristol Meyers Squibb, Hoffmann-La Roche Inc., Cytheris SA, LG Life Sciences Ltd, Enzo Biochem, Digna Biotech, Daewoong Pharma and IRX Therapeutics.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include a strategic competitor assessment, a market characterization, the unmet needs and the implications for the Hepatitis B market

Reasons to buy



The report will enhance your decision making capability. It will allow you to:

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipelines.

- Develop business strategies by understanding the trends shaping and driving the global Hepatitis B therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to affect the global Hepatitis B therapeutics market in the future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.

- What’s the next big thing in the global Hepatitis B therapeutics market landscape? Identify, understand and capitalize.
1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 HEPATITIS B: INTRODUCTION

2.1 GlobalData Pipeline Report Guide

3 HEPATITIS B: MARKET CHARACTERIZATION

3.1 Overview
3.2 Hepatitis B Therapeutics Market Size
3.3 Hepatitis B Therapeutics Market Forecast and CAGR
3.4 Drivers and Barriers for the HBV Market
  3.4.1 Drivers of the HBV Market
  3.4.2 Barriers for the Hepatitis B Therapeutics Market
3.5 Opportunity and Unmet Need
3.6 Key Takeaway

4 HEPATITIS B THERAPEUTICS MARKET: COMPETITIVE ASSESSMENT

4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profile for the Major Marketed Products in the Hepatitis B Therapeutics Market
  4.3.1 Baraclude (Entecavir)
  4.3.2 Viread (Tenofovir)
  4.3.3 Tyzeka (Telbivudine)
  4.3.4 Hepsera (Adefovir Dipivoxil)
  4.3.5 Epivir-HBV (lamivudine)
  4.3.6 Pegasys
4.4 Key Takeaway

5 HEPATITIS B: PIPELINE ASSESSMENT

5.1 Overview
5.2 Strategic Pipeline Assessment
  5.2.1 Technology Trends Analytic Framework
5.3 Hepatitis B Therapeutics – Promising Drugs under Clinical Development
5.4 Drugs under Clinical Development
  5.4.1 Entecavir plus Adefovir combination therapy
  5.4.2 Tenofovir plus Emtricitabine combination therapy
  5.4.3 Pegylated Interferon Alfa-2a + Adefovir
5.5 Hepatitis B Therapeutics Market – Clinical Pipeline by Mechanism of Action
5.6 Hepatitis B Therapeutics Pipeline – Pipeline by Clinical Phases of Development
  5.6.1 Hepatitis B Therapeutics – Phase III Clinical Pipeline
  5.6.2 Hepatitis B Therapeutics – Phase II Clinical Pipeline
  5.6.3 Hepatitis B Therapeutics – Phase I Clinical Pipeline
  5.6.4 Hepatitis B Therapeutics – Preclinical Pipeline
5.7 Discontinued / Suspended Drugs for Hepatitis B
5.8 Key Takeaway

6 HEPATITIS B THERAPEUTICS MARKET: IMPLICATIONS FOR FUTURE MARKET COMPETITION

7 HEPATITIS B THERAPEUTICS MARKET: FUTURE PLAYERS IN THE HEPATITIS B THERAPEUTICS MARKET

7.1 Introduction
7.2 Bristol-Myers Squibb
  7.2.1 Overview
  7.2.2 Business Description
  7.2.3 Infectious Disease Portfolio
  7.2.4 Hepatitis B Therapeutics Product Portfolio
7.3 Gilead Sciences, Inc.
  7.3.1 Overview
  7.3.2 Business Description
  7.3.3 Infectious Disease Portfolio
  7.3.4 Hepatitis B Product Portfolio
7.4 Hoffmann-La Roche Ltd
  7.4.1 Overview
  7.4.2 Business Description
  7.4.3 Infectious Disease Portfolio

8 HEPATITIS B THERAPEUTICS MARKET: APPENDIX

8.1 Definitions
8.2 Scope of Pipeline Research
8.3 Abbreviations
8.4 Research Methodology
  8.4.1 Coverage
  8.4.2 Secondary Research
  8.4.3 Forecasting
  8.4.4 Primary Research
  8.4.5 Expert Panels
8.5 Contact Us
8.6 Disclaimer
8.7 Sources 4

LIST OF TABLES

Table 1: Hepatitis B Therapeutics, Global, Market Revenue ($m), 2001–2009
Table 2: Hepatitis B Therapeutics, Global, Market Forecast ($m), 2009–2017
Table 3: Major Marketed Product in the Hepatitis B Therapeutics Market, 2010
Table 4: Hepatitis B Therapeutics – Promising Drugs Under Clinical Development, 2010
Table 5: Hepatitis B Therapeutics – Phase III Clinical Pipeline, 2010
Table 6: Hepatitis B Therapeutics – Phase II Clinical Pipeline, 2010
Table 7: Hepatitis B Therapeutics – Phase I Clinical Pipeline, 2010
Table 8: Hepatitis B Therapeutics – Preclinical Pipeline, 2010
Table 9: Discontinued Drugs for Hepatitis B, 2010
Table 10: Bristol-Myer Squibb – Infectious Disease and Hepatitis B Therapeutics Pipeline, 2010
Table 11: Gilead Sciences Inc. – Infectious Disease and Hepatitis B Therapeutics Pipeline, 2010
Table 12: Hoffman-La Roche Ltd. – Infectious Disease and Hepatitis B Therapeutics Pipeline, 2010

LIST OF FIGURES

Figure 1: Hepatitis B Therapeutics, Global, Market Revenue ($m), 2001–2009
Figure 2: Hepatitis B Therapeutics, Global, Market Forecast ($m), 2009–2017
Figure 3: Opportunity and Unmet Need in the Hepatitis B Therapeutics Market, 2010
Figure 4: Strategic Competitor Assessment of the Major Marketed Products for Hepatitis B, 2010
Figure 5: Technology Trends Analytic Framework of the Hepatitis B Therapeutics Pipeline, 2010
Figure 6: Technology Trends Analytic Framework of Hepatitis B Therapeutics Pipeline, Description, 2010
Figure 7: Hepatitis B Therapeutics Market – Clinical Pipeline by Mechanism of Action, 2010
Figure 8: Hepatitis B Therapeutics Pipeline by Phases of Clinical Development, 2010
Figure 9: Implications for Future Market Competition in the Hepatitis B Therapeutics Market, 2010
Figure 10: Hepatitis B Therapeutics Market – Clinical Pipeline by Company, 2010
Figure 11: GlobalData Market Forecasting Model 39

COMPANIES MENTIONED

Bristol-Myers Squibb
Gilead Sciences, Inc
Hoffmann-La Roche Ltd

Ask Your Question

Hepatitis B - Pipeline Assessment and Market Forecasts to 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: